For decades, the scientific theory of depression focused on chemicals — serotonin, norepinephrine and dopamine. Nearly every ...

NRx Pharmaceuticals has been awarded Fast Track designation and recently received FDA guidance anticipating NRx’s upcoming New Drug Application for NRX-100 (preservative free ketamine) to treat ...

When Jason Prinzo was diagnosed with depression, he was five years old. His father was an alcoholic and a drug addict who was ...

Treatment-resistant depression affects millions of Americans who have tried multiple antidepressants without finding relief. After cycling through different medications, therapy approaches, and ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Ketamine is increasingly being used as an off-label treatment for depression, but researchers have found it might not provide any long term benefits. Depression has been recognised by the World Health ...

Roughly one in ten Americans suffers from major depressive disorder (MDD) at any given time. In total, up to 20 percent of people will deal with its symptoms at some point in their lives. Despite its ...

Off-label ketamine is being increasingly used in clinical practice for treatment-resistant depression. Serial infusions of ketamine were no better than midazolam infusions for hospitalized patients ...

A recent study published in the journal Neuropharmacology provides evidence that a single dose of the psychedelic compound ...

Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results from its phase 1 ...

June 7, 2012 (Phoenix, Arizona) — The administration of 6 low-dose intravenous infusions of the fast-acting drug ketamine over 2 weeks shows efficacy in improving symptoms in patients with ...